Comparing the efficacy of enteral and parenteral zinc supplementation in children

Comparing the effectiveness of enteral and parenteral zinc supplementation in children hospitalized in the intensive care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190522043672N4

Enrollment

105

Registered

2023-05-09

Start date

2023-04-19

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

zinc deficiency. Dietary zinc deficiency

Interventions

Intervention 1: Intervention group 1: A vial of zinc supplement manufactured by Dr. Rajabi Pharmaceutical Company (Special Shares) at the rate of 500 µg/kg/day is used enterally for seven days. Interv

Eligibility

Sex/Gender

All

Age

1 Months to 10 Years

Inclusion criteria

Inclusion criteria: Age between 1 month and 10 years Admission to intensive care units of Akbar Hospital Predicted length of stay in the pediatric intensive care unit of more than 4 days

Exclusion criteria

Exclusion criteria: Lack of parental consent Renal failure Multi-organ damage Known zinc deficiency (eg enteropathy acrodermatitis) Pre-existing or newly diagnosed bone marrow failure or diabetes mellitus In-place care or anticipated survival restriction orders.

Design outcomes

Primary

Measure	Time frame
C-Reactive Protein (CRP). Timepoint: The first day before the start of the intervention and seven days after the start of the intervention. Method of measurement: (ELISA) Enzyme-linked immunosorbent.;Plasma copper to zinc ratio. Timepoint: The first day before the start of the intervention and seven days after the start of the intervention. Method of measurement: Plasma mass spectrometry.;Complete blood count. Timepoint: The first day before the start of the intervention and seven days after the start of the intervention. Method of measurement: complete blood cell count test device.	—

Measure

Time frame

C-Reactive Protein (CRP). Timepoint: The first day before the start of the intervention and seven days after the start of the intervention. Method of measurement: (ELISA) Enzyme-linked immunosorbent.;Plasma copper to zinc ratio. Timepoint: The first day before the start of the intervention and seven days after the start of the intervention. Method of measurement: Plasma mass spectrometry.;Complete blood count. Timepoint: The first day before the start of the intervention and seven days after the start of the intervention. Method of measurement: complete blood cell count test device.

—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: The seventh day after the start of the intervention. Method of measurement: Completing the checklist.;Duration of ventilator use (days). Timepoint: The seventh day after the start of the intervention. Method of measurement: Completing the checklist.;Mortality percentage. Timepoint: The seventh day after the start of the intervention. Method of measurement: Completing the checklist.	—

Measure

Time frame

Duration of hospitalization. Timepoint: The seventh day after the start of the intervention. Method of measurement: Completing the checklist.;Duration of ventilator use (days). Timepoint: The seventh day after the start of the intervention. Method of measurement: Completing the checklist.;Mortality percentage. Timepoint: The seventh day after the start of the intervention. Method of measurement: Completing the checklist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Sezavar

Mashhad University of Medical Sciences

sezavardm@mums.ac.ir+98 51 3870 9225

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026